Bladder cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• MYC 0
• ERK 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

24 of 42+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Artificial Intelligence Enhanced Detection and Monitoring of Bladder Cancer

  Vesica Corporation· San Marcos, United States· US$1,200,764 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort

  Veterans Education/Res/Assn/North/Ne· White River Junction, United States· US$594,869 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Population modeling for bladder cancer prevention and control

  Brown University· Providence, United States· US$1,231,387 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · P50

  SPORE in Bladder Cancer

  Sloan-Kettering Inst Can Research· New York, United States· US$2,491,899 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the effect of high methionine availability on cancer progression

  University of Southern California· Los Angeles, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €2,000,000· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €197,264· until Mar 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Ireland· EU contribution €328,495· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Ireland· EU contribution €13,615,935· until Dec 2029· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Israel· EU contribution €2,498,731· until Nov 2026

10 of 192 running projects, newest first. Listed amounts together: US$123.2m + €36.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Source

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Source

• TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

  NCT07038928· AstraZeneca· Source

• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Seagen, a wholly owned subsidiary of Pfizer· Source

• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Seagen, a wholly owned subsidiary of Pfizer· Source

• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· AstraZeneca· Source

• Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

  NCT07379268· Qilu Hospital of Shandong University· Source

• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

  NCT05786716· Cancer Research UK· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 79
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 78
• Genome-Wide Association Study 18

• Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.

  Cancer Lett, Sept 2026

• Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non-Invasive Diagnosis of Bladder Cancer.

  Cancer Sci, Jul 2026

• Integrating whole-genome bisulfite sequencing and TCGA data reveals methylation patterns associated with the MTHFR 677 C > T Variant.

  Sci Rep, Jun 2026

• Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes.

  Cancer Res Commun, Apr 2026

• Molecular residual disease assessment in colorectal and bladder cancer by somatic structural variant analysis of cell-free DNA whole-genome sequencing data.

  J Transl Med, Feb 2026

• Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.

  Int J Mol Sci, Dec 2025

• Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing.

  BMC Cancer, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.